Physician No program year No payments reported Source: CMS Open Payments, 2026 publication

Karen Prida

Internal Medicine Pembroke Pines, FL

NPI 1033379896 CMS profile 591868

501 Nw 103Rd Ave, Pembroke Pines, FL 33026

Open in the dashboard

General payments

$0

None reported

Research payments

$0

Paid to them · None reported

Ownership & investment interest

$0

None reported

The CMS Open Payments record contains no reported payments to Karen Prida of Pembroke Pines, FL.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

Prescribing to Medicare patients

Part D · data year 2024 · 110 drugs

Part D claims

5,354

Median for Internal Medicine: 777

Drug cost

$249,582

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 64 $42,006
Januvia Sitagliptin Phosphate Brand 39 $34,803
Jardiance Empagliflozin Brand 40 $34,241
Ozempic Semaglutide Brand 18 $16,646
Myrbetriq Mirabegron Brand 28 $14,151
Entresto Sacubitril/Valsartan Brand 21 $13,653
Rybelsus Semaglutide Brand 11 $10,187
Farxiga Dapagliflozin Propanediol Brand 11 $8,201
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 69 $4,736
Lantus Insulin Glargine,hum.Rec.Anlog Brand 35 $3,619

The 10 drugs with the highest cost, of 110 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record